Experts debate AI's ability to outperform doctors and urge wider healthcare adoption
Updated
Updated · CNBC · Apr 28
Experts debate AI's ability to outperform doctors and urge wider healthcare adoption
10 articles · Updated · CNBC · Apr 28
At CNBC's CONVERGE LIVE in Singapore, Insilico Medicine CEO Alex Zhavoronkov and Biocon CEO Shreehas Tambe discussed AI tools like ChatGPT Health and Amazon's HealthAI, highlighting rapid drug research and consumer health applications.
Zhavoronkov claimed some consumer AI models match or exceed doctors' capabilities for basic health queries, while Tambe stressed the need for human validation to avoid errors as technology adoption grows.
AI is reducing drug development timelines from over four years to 18 months, but experts emphasize a cautious approach and the importance of human oversight as AI's role in healthcare expands.
With millions skipping doctor visits for AI, are we heading toward a public health crisis driven by algorithms?
AI can design new drugs in months, but how do we solve the bottleneck of physically testing them?
When AI health advice proves harmful, who is legally to blame: the user, the developer, or the doctor?
Your health data isn't HIPAA protected on most AI apps. Is convenience worth this massive privacy gamble?
Are we ignoring the massive environmental cost of the data centers powering life-saving healthcare AI?
AI is acing medical exams but failing patients. Why does it struggle so much with real-world human interaction?